LeukoPrint®
Hematologic Malignancy Molecular Karyotyping Test
LeukoPrint® is a molecular karyotyping test designed to complement conventional cytogenetic approaches in hematologic malignancy diagnostics. lt employs shallow whole-genome sequencing (sWGS) to deliver comprehensive, high-resolution genome coverage for the detection of clinically significant copy number aberration (CNA) and copy neutral loss of heterozygosity (CN-LOH), providing advantages over traditional karyotyping and fluorescence in situ hybridization (FlSH).
Molecular karyotyping
Precision diagnosis
Risk stratification
Therapy guidance
Highlights
- LeukoPrint® performs shallow whole-genome sequencing (sWGS, at 1× coverage) on bone marrow samples to identify genome-wide CNA and CN-LOH.
- When combined with traditional cytogenetic methods, it enables more accurate diagnosis,classification, risk-stratification, and ultimately guides risk-adapted therapy for hematologic malignancies.
Testing time
First-line diagnostic adjunct
enhances sensitivity in
suspected hematologic
malignancies.
Karyotyping failure rescue
provides full genomic profiling when standard
karyotyping fails.
Complex case resolution
reveals cryptic abnormalities when karyotyping/FISH
are inconclusive.
Critical variant detection
identifies CN-LOH
undetectable by
karyotyping/FISH.
How it works
Order
Consult your doctor to order through a local healthcare partner
Blood draw
2-4 mL bone marrow is collected and delivered to the central lab
Testing
Detection is performed using next generation sequencing (NGS) platform
Reporting
Results are ready within 10 working days after the sample arrives at the central lab
